- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02183155
Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects
July 4, 2014 updated by: Boehringer Ingelheim
A Double Blind, Randomized, Parallel Group Trial to Compare the Effect of Three Doses of Meloxicam Tablets (7.5, 15 and 30 mg) With Placebo on Bleeding Time in Healthy Subjects; With Extended-release Indomethacin Capsules 75 mg (Open-label) as an Active Control to Assess Trial Sensitivity.
The primary purpose of this study was to evaluate the effect of meloxicam tablets (7.5, 15 mg and 30 mg) with meloxicam placebo.
Extended-release indomethacin capsules (75 mg) was an active control to assess trial sensitivity on bleeding time in healthy subjects.
The secondary aim of this study was to assess effects of treatment on other platelet function and coagulation parameters.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
82
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male or female subjects between the ages of 18 and 55 years
- Negative urine pregnancy test on Day1 for females of childbearing potential
- Weight within +/- 20 percent of ideal weight according to the Metropolitan Life Height and Weight chart
- Willing and able to cooperate with the investigator and his/her staff
- Written informed consent in accordance with GCP (Good Clinical Practice) and local legislation
Exclusion Criteria:
- Any finding, medical condition or dietary restriction that, in the investigator's opinion, may interfere with optimal participation in the study or produce a significant risk to the subject
- In the opinion of the investigator, the subject has any disease or condition that may result in altered absorption, excess accumulation, or impaired metabolism or excretion of the trial medications
- A known or suspected hypersensitivity to any of the trial medications or their excipients or any other NSAIDs (Non-Steroid Anti-Inflammatory Drug)
- A history of gastrointestinal ulcer, perforation or bleeding
- A history of cerebrovascular bleeding or any other bleeding disorder
- Women of childbearing potential not using adequate contraception (e.g, intrauterine device, contraceptive pills, Depo-Provera® implant, barrier device) for at least 3 months prior to, and for the duration of trial participation. It should be noted that NSAIDs may interfere with the effectiveness of intrauterine devices
- History of bronchial asthma
- Use of any medications that might influence the results of the trial
- Use of anticoagulants, including warfarin, heparin, ticlopidine, clopidogrel or aspirin
Any laboratory value outside the normal range that is considered clinically significant by the investigator. In addition, subjects with the following specific laboratory values will not be allowed:
- A serum creatinine concentration at baseline > 1.5 mg/dl
- SGOT (serum glutamic-oxaloacetic transaminase) or SGPT (serum glutamic-pyruvic transaminase) liver enzymes results at baseline > 1.5 times the upper limit of normal
- A hemoglobin concentration < 10.5 g/dl
- A white cell count < 3500/mm³
- A platelet < 100,000/mm³ or a documented abnormal bleeding time, platelet aggregation, thromboxane B2 synthesis, thromboplastin time (PT) or activated partial thromboplastin time (APTT)
- Inability to refrain from smoking on testing days
- Participation in another trial with an investigational drug within 30 days of entering the trial
- Subjects with increased keloid formation
- Previous surgery of the gastrointestinal tract (except appendectomy)
- Participation in excessive physical activities (≤ 5 days prior to administration)
- Current drug or alcohol abuse
- Small or difficult to locate arm veins that would impair the clinician's ability to draw blood samples
- Homeopathic medication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: Meloxicam - low
|
|
Experimental: Meloxicam - medium
|
|
Experimental: Meloxicam - high
|
|
Active Comparator: Extended-release indomethacin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in bleeding time
Time Frame: up to 6 hours post-dose at day 8
|
up to 6 hours post-dose at day 8
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with adverse events
Time Frame: up to 8 days
|
up to 8 days
|
Change from baseline in platelet aggregation
Time Frame: up to 6 hours post-dose at day 8
|
up to 6 hours post-dose at day 8
|
Change from baseline in Platelet thromboxane B2 synthesis (TXB2 synthesis)
Time Frame: up to 6 hours post-dose at day 8
|
up to 6 hours post-dose at day 8
|
Change in Thromboplastin Time (PT)
Time Frame: up to 6 hours post-dose at day 8
|
up to 6 hours post-dose at day 8
|
Change in Activated Partial Thromboplastin Time (APTT)
Time Frame: up to 6 hours post-dose at day 8
|
up to 6 hours post-dose at day 8
|
Change in Platelet Count
Time Frame: up to 6 hours post-dose at day 8
|
up to 6 hours post-dose at day 8
|
Change in Leucocyte Activation
Time Frame: Day 1 and 6 hours post-dose at day 8
|
Day 1 and 6 hours post-dose at day 8
|
Plasma levels of meloxicam
Time Frame: pre-dose, 3 and 6 hours post-dose at day 8
|
pre-dose, 3 and 6 hours post-dose at day 8
|
Plasma levels of indomethacin
Time Frame: pre-dose, 3 and 6 hours post-dose at day 8
|
pre-dose, 3 and 6 hours post-dose at day 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2000
Primary Completion (Actual)
September 1, 2000
Study Registration Dates
First Submitted
July 4, 2014
First Submitted That Met QC Criteria
July 4, 2014
First Posted (Estimate)
July 8, 2014
Study Record Updates
Last Update Posted (Estimate)
July 8, 2014
Last Update Submitted That Met QC Criteria
July 4, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Hemorrhage
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Reproductive Control Agents
- Cyclooxygenase 2 Inhibitors
- Gout Suppressants
- Tocolytic Agents
- Indomethacin
- Meloxicam
Other Study ID Numbers
- 107.236
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States